Novartis raises FY core operating income guidance after Q3 sales and margin growth
FROM THE WIRE · FINANCE.YAHOO.COM
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR Third quarter Q3 net sales grew +4% (cc¹, +4% USD), with core operating income¹ +10% (cc, +11% USD) Sales growth driven by priority brands including Kisqali (+37% cc), Kesimpta (+22% cc), Scemblix (+67% cc), Leqvio…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA pharma mega-cap raised full-year core operating income guidance, a significant signal for the sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 net sales grew 4% at constant currency.
- 02Core operating income rose 10% and the core margin reached 41.6%.
- 03Q3 free cash flow was USD 5.1 billion, down 18% in USD terms.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Novartis AG153.81 USDMarket closedtoday +1.78%Positive Novartis AG150.12 USDMarket closedtoday +0.21%Positive 68CT—n/aPositive RMS—n/aPositive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets